The research behind our technology began over 12 years ago in the laboratory of Tissue Engineering and Regenerative Medicine of the University of Zurich. Following the completion of preclinical Proof of Concept studies demonstrating the efficacy and safety of our therapy for the treatment of stress urinary incontinence in 2015, an international consortium led by the University of Zurich was established with the goal of transferring these results from the lab to the clinic. This project was given the acronym MUS.I.C. www.music2020.ch and was completely funded through a H2020 grant from the European Union. Having completed all necessary documentation and the GMP validation of the production process, the first in-human trial using our novel therapeutic approach began in January 2020 at the University Hospital of Zurich and was completed successfully in September 2021.

To ensure that this promising therapy and technology is developed further clinically as well as commercially and made available to the millions of patients in need, we decided to intensify our efforts and found a startup. Thus, MUVON Therapeutics was born.

Following its founding MUVON was being accelerated by the Wyss Zurich Translational Center, which enabled the setup and completion of a phase II clinical trial from 2021-2025.